Loading company…
Surginex develops nanoparticle-based drug delivery technology and scientific services.
Founded in 2020 and based in Seoul, Surginex develops drug delivery technology using nanoparticles such as exosomes and liposomes. Its Odysseus platform applies AI-based molecular dynamics to model drug delivery and cellular structures. The company also provides investigational kits, custom exosomes, genetic testing, RNA and protein analysis, CRISPR/Cas9 design, material analysis and histopathology. It raised KRW 8.5 billion in venture funding in March 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in